Skip to main content

Carmen Tur Gomez

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Carmen Tur Gomez

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Aprendizaje profundo para una evaluación temprana del riesgo de progresión en la esclerosis múltiple: desde la RM estructural rutinaria hasta la histopatología, pasando por la neuroimagen cuantitativa

IP: Carmen Tur Gomez
Collaborators: Enrique Rodríguez Zafra, Elena Huerga Núñez, Jordina Beltran Valles
Funding agency: Instituto de Salud Carlos III
Funding: 152500
Reference: PI24/01277
Duration: 01/01/2025 - 31/12/2027

Investigation of pathology-informed neuroimaging predictors of progression independent of relapse activity at the first attack of multiple sclerosis: from histopathology to routinely acquired anatomical MRI, through advanced quantitative neuroimaging and

IP: Carmen Tur Gomez
Collaborators: Carlos Domínguez Pérez, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 242500
Reference: CP23/00117
Duration: 01/01/2024 - 31/12/2028

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Teresa Macarulla Mercadé, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Ana Vivancos Prellezo, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Sandra Mancilla Zamora, Ana Zabalza de Torres, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Paolo Giovanni Nuciforo, Tian Tian, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

Incorporación al CIBER de enfermedades neurodegenerativas como grupo de esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Jordi Rio Izquierdo, Carmen Tur Gomez, Incorporación al CIBER de enfermedades neurodegenerativas como grupo de esclerosis múltiple, Luciana Midaglia Fernandez, Joaquin Castillo Justribo, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Instituto de Salud Carlos III
Funding: 48000
Reference: CB22/05/00047
Duration: 13/12/2022 - 12/12/2023

Related news

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Isabel Mª Garlito Pérez

Isabel Mª Garlito Pérez

Main researcher
Multidisciplinary Nursing Research Group
Read more
Hug Cuellar Calabria

Hug Cuellar Calabria

Senior researcher
Molecular Imaging and Therapy
Read more
David Hernandez Morales

David Hernandez Morales

Research technician
Stroke research
Read more
Rosa Elisabet Ruiz Hudd

Rosa Elisabet Ruiz Hudd

Predoctoral researcher
Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.